Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
138
olanzapine 2.5 mg/day for 28 days
olanzapine 5 mg/day for 28 days
placebo 1 tab/day for 28 days
Faculty of Medicine Siriraj Hospital
Bangkok, Thailand
RECRUITINGDivision of medical oncology, department of medicine Siriraj Hospital
Bangkok, Thailand
RECRUITINGno greater than 5% weight loss in olanzapine 2.5 mg versus placebo
proportion of patients with olanzapine 2.5 mg without greater or equal to 5% weight loss compared to placebo
Time frame: 4 weeks
no greater than 5% weight loss in olanzapine 5 mg versus placebo
proportion of patients with olanzapine 5 mg without greater or equal to 5% weight loss compared to placebo
Time frame: 4 weeks
numerical scale of anorexia
proportion of patients with decreased numerical scale of anorexia
Time frame: 4 weeks
body weight
body weight change from baseline
Time frame: week 2 and 4
adverse effects
adverse effects
Time frame: week 1, 2, 3, 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.